Literature DB >> 33258388

Ulcerative Colitis-associated E. coli pathobionts potentiate colitis in susceptible hosts.

Hyungjun Yang1, Hengameh Chloé Mirsepasi-Lauridsen2,3, Carsten Struve2, Joannie M Allaire1, Adeline Sivignon4,5, Wayne Vogl6, Else S Bosman1, Caixia Ma1, Abbas Fotovati1, Gregor S Reid1, Xiaoxia Li7, Andreas Munk Petersen8,9, Sébastien G Gouin10, Nicolas Barnich4,5, Kevan Jacobson1, Hong Bing Yu1, Karen Angeliki Krogfelt2, Bruce A Vallance1,11.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition linked to intestinal microbial dysbiosis, including the expansion of E. coli strains related to extra-intestinal pathogenic E. coli. These "pathobionts" exhibit pathogenic properties, but their potential to promote UC is unclear due to the lack of relevant animal models. Here, we established a mouse model using a representative UC pathobiont strain (p19A), and mice lacking single immunoglobulin and toll-interleukin 1 receptor domain (SIGIRR), a deficiency increasing susceptibility to gut infections. Strain p19A was found to adhere to the cecal mucosa of Sigirr -/- mice, causing modest inflammation. Moreover, it dramatically worsened dextran sodium sulfate-induced colitis. This potentiation was attenuated using a p19A strain lacking α-hemolysin genes, or when we targeted pathobiont adherence using a p19A strain lacking the adhesin FimH, or following treatment with FimH antagonists. Thus, UC pathobionts adhere to the intestinal mucosa, and worsen the course of colitis in susceptible hosts.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Ulcerative Colitis; in vivo mouse model; intestinal microbiota

Year:  2020        PMID: 33258388      PMCID: PMC7781664          DOI: 10.1080/19490976.2020.1847976

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  65 in total

Review 1.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

2.  Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells.

Authors:  J Boudeau; N Barnich; A Darfeuille-Michaud
Journal:  Mol Microbiol       Date:  2001-03       Impact factor: 3.501

3.  Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death.

Authors:  A L Glasser; J Boudeau; N Barnich; M H Perruchot; J F Colombel; A Darfeuille-Michaud
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements.

Authors:  R Lutz; H Bujard
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

Review 5.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

6.  The Muc2 mucin coats murine Paneth cell granules and facilitates their content release and dispersion.

Authors:  Martin Stahl; Sarah Tremblay; Marinieve Montero; Wayne Vogl; Lijun Xia; Kevan Jacobson; Alfredo Menendez; Bruce A Vallance
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-04-26       Impact factor: 4.052

7.  Comparative genomics of Escherichia coli isolated from patients with inflammatory bowel disease.

Authors:  Rebecca Munk Vejborg; Viktoria Hancock; Andreas M Petersen; Karen A Krogfelt; Per Klemm
Journal:  BMC Genomics       Date:  2011-06-15       Impact factor: 3.969

8.  Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation.

Authors:  Benoit Chassaing; Gayathri Srinivasan; Maria A Delgado; Andrew N Young; Andrew T Gewirtz; Matam Vijay-Kumar
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

9.  Dual ligand/receptor interactions activate urothelial defenses against uropathogenic E. coli.

Authors:  Yan Liu; Sylvie Mémet; Ricardo Saban; Xiangpeng Kong; Pavel Aprikian; Evgeni Sokurenko; Tung-Tien Sun; Xue-Ru Wu
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

10.  Extraintestinal pathogenic Escherichia coli are associated with intestinal inflammation in patients with ulcerative colitis.

Authors:  Hengameh C Mirsepasi-Lauridsen; Sofie Ingdam Halkjaer; Esben Munk Mortensen; Magnus C Lydolph; Inge Nordgaard-Lassen; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

View more
  4 in total

1.  The Fis Nucleoid Protein Negatively Regulates the Phase Variation fimS Switch of the Type 1 Pilus Operon in Enteropathogenic Escherichia coli.

Authors:  Zeus Saldaña-Ahuactzi; Jorge Soria-Bustos; Verónica I Martínez-Santos; Jorge A Yañez-Santos; Ygnacio Martínez-Laguna; María Lilia Cedillo-Ramirez; José L Puente; Jorge A Girón
Journal:  Front Microbiol       Date:  2022-04-28       Impact factor: 6.064

2.  Dextran Sulphate Sodium Acute Colitis Rat Model: A Suitable Tool for Advancing Our Understanding of Immune and Microbial Mechanisms in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Petra Adamkova; Petra Hradicka; Helena Kupcova Skalnikova; Veronika Cizkova; Petr Vodicka; Silvia Farkasova Iannaccone; Monika Kassayova; Sona Gancarcikova; Vlasta Demeckova
Journal:  Vet Sci       Date:  2022-05-16

Review 3.  Negative Regulation of the IL-1 System by IL-1R2 and IL-1R8: Relevance in Pathophysiology and Disease.

Authors:  Domenico Supino; Luna Minute; Andrea Mariancini; Federica Riva; Elena Magrini; Cecilia Garlanda
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

4.  Phylogrouping and characterization of Escherichia coli isolated from colonic biopsies and fecal samples of patients with flare of inflammatory bowel disease in Iran.

Authors:  Banafsheh Nadalian; Bahareh Nadalian; Hamidreza Houri; Shabnam Shahrokh; Mohammad Abdehagh; Abbas Yadegar; Gholamhossein Ebrahimipour
Journal:  Front Med (Lausanne)       Date:  2022-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.